2024年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2024)将于当地时间12月6日-8日在新加坡召开,旨在展示和讨论亚洲地区肿瘤学领域的最新临床科研进展,进一步推动学术交流和共同进步。
目前,ESMO Asia官网已公布了摘要标题,40+项中国研究入选口头报告环节:LBA(Late Breaking Abstract )2项、O(Oral)16项、MO(Mini Oral)24项,彰显我国在肿瘤学领域的创新力量和科研实力。【肿瘤资讯】特别整理如下,带您一睹中国学者在ESMO Asia 2024上的学术风采。
胸部恶性肿瘤
摘要号:625O
英文标题:Efficacy and safety of Lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-controlled multicenter phase II trial
标题:Lucitanib(AL3810)二线或后线治疗晚期复发或转移性胸腺癌的有效性和安全性:一项随机、双盲、安慰剂对照、多中心II期试验
讲者:方文涛 (上海市胸科医院)
摘要号:LBA6
英文标题:PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
标题:PACIFIC-5:一项在同步或序贯放化疗(cCRT或sCRT)后无进展的不可切除III期NSCLC患者中进行的度伐利尤单抗巩固治疗的III期研究
讲者:吴一龙 (广东省人民医院)
摘要号:627MO
英文标题:POD1UM-304: Phase 3 Study of Retifanlimab Plus Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Therapy For Nonsquamous or Squamous Metastatic Non–Small Cell Lung Cancer (mNSCLC)
标题:POD1UM-304:Retifanlimab联合含铂化疗作为非鳞状或鳞状转移性非小细胞肺癌一线治疗的III期研究
讲者:陆舜(上海市胸科医院)
摘要号:614MO
英文标题:A Phase Ⅱ Study of Becotatug (JMT101) in Combination with Osimertinib (Osi) in Patients (pts) with classical EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (BOOSTER Study)
标题:Becotatug(JMT101)联合奥希替尼治疗典型EGFR突变型非小细胞肺癌患者的Ⅱ期研究(BOOSTER研究)
讲者:张力(中山大学肿瘤防治中心)
摘要号:630MO
英文标题:First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort
标题:一线奥希替尼±铂类-培美曲塞化疗治疗EGFR突变晚期非小细胞肺癌:FLAURA2亚洲队列
讲者:杨志新 (中国台湾大学医学院附设医院癌医中心分院)
摘要号:629MO
英文标题:ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC)
标题:ALESIA 7年更新:在亚洲初治晚期ALK+非小细胞肺癌患者中比较阿来替尼与克唑替尼
讲者:周彩存 (同济大学附属东方医院)
乳腺癌
摘要号:36O
英文标题:18F-fluoroestradiol (18F-FES) PET/CT guided first-line treatment for HR+/HER2- metastatic breast cancer patients: experience from real-world
中文标题:18F-氟雌二醇(18F-FES)PET/CT引导下的HR+/HER2-转移性乳腺癌患者一线治疗:来自真实世界的经验
讲者:王碧芸(复旦大学附属肿瘤医院)
摘要号:27O
英文标题:Assessment of Overall Survival Benefit from Neoadjuvant Chemotherapy in Elderly HER-2 Negative Breast Cancer Patients: A Population-Based Study
中文标题:HER2-老年乳腺癌患者新辅助化疗总生存获益:一项基于人群的研究
讲者:吕文杰(上海交通大学医学院附属新华医院)
摘要号:2O
英文标题:Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2−early breast cancer (EBC)
中文标题:评估瑞波西利(RIB)+非甾体芳香化酶抑制剂(NSAI)治疗HR+/HER2-早期乳腺癌的NATALEE研究亚洲和非亚洲患者分析
讲者:徐兵河(中国医学科学院肿瘤医院)
摘要号:37MO
英文标题:HER2-low Heterogeneity and Its Impact on Benefit from Trastuzumab Deruxtecan in Metastatic Breast Cancer
中文标题:HER2低表达异质性及其对转移性乳腺癌患者T-DXd治疗获益的影响
讲者:邹宇田(中山大学肿瘤防治中心)
摘要号:38MO
英文标题:Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Results from TROPION-Breast01 China cohort
中文标题:Dato-DXd vs化疗(CT)用于经治不可手术/转移性HR+/HER2-乳腺癌:TROPION-Breast01研究中国队列结果
讲者:王树森(中山大学肿瘤防治中心)
摘要号:28MO
英文标题:Dynamic evolution of vascular features based on magnetic resonance imaging to predict pathological response and survival outcomes in breast cancer patients undergoing neoadjuvant chemotherapy
中文标题:基于磁共振成像的血管特征动态演变预测新辅助化疗乳腺癌患者的病理学缓解和生存预后
讲者:吴琼(上海交通大学医学院附属仁济医院)
妇科恶性肿瘤
摘要号:372O
英文标题:Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: an open-label, non-comparative, randomised, phase 2 trial
中文标题:Balstilimab(bal)单药或与Zalifrelimab(zal)联合治疗宫颈癌:一项开放标签、非比较性、随机化、2期试验
讲者:吴令英(中国医学科学院肿瘤医院)
摘要号:373O
英文标题:First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study
中文标题:艾帕洛利单抗/托沃瑞利单抗(QL1706)+化疗(chemo)±贝伐珠单抗(BEV)一线治疗复发/转移性宫颈癌(r/mCC):2期DUBHE-C-204研究更新结果
讲者:王丹波(辽宁省肿瘤医院)
摘要号:374O
英文标题:The burden and trends of gynecological cancers in Asia from 1980 to 2021: A systematic analysis for the Global Burden of Disease Study 2021
中文标题:1980年-2021年亚洲妇科肿瘤负担和趋势:2021年全球疾病负担研究系统分析
讲者:Run Miao (中国合肥)
摘要号:376MO
英文标题:The impact of crossover to surgery in the no-surgery group on the survival: a post-hoc analysis of the SOC-1 trial
中文标题:非手术组交叉到手术组对生存的影响:SOC-1试验事后分析
讲者:Lina Shen (中国上海)
摘要号:377MO
英文标题:Lymph node dissection before initial treatment for locally advanced cervical cancer: a systematic review and meta-analysis
中文标题:局部晚期宫颈癌初始治疗前淋巴结清扫术:系统评价和荟萃分析
讲者:He Zhang (中国北京)
摘要号:378MO
英文标题:Efficacy and Safety of Disitamab Vedotin in Treatment of HER2 Expressed Advanced or Recurrent Gynecological Cancers
中文标题:维迪西妥单抗治疗HER2表达晚期或复发性妇科肿瘤的疗效和安全性
讲者:王东雁 中山大学孙逸仙纪念医院
胃肠肿瘤
摘要号:126O
英文标题:Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
中文标题:纳武利尤单抗(NIVO)联合伊匹木单抗(IPI)对比仑伐替尼( LEN)或索拉非尼(SOR)一线(1L)治疗不可切除肝细胞癌(uHCC)的疗效:CheckMate 9DW研究亚洲亚组分析
讲者:Thomas Yau (中国香港)
摘要号:129MO
英文标题:Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive (HER2+) advanced gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric06 (DG-06) final analysis
中文标题:德曲妥珠单抗(T-DXd)用于治疗既往经治、HER2阳性晚期胃或胃食管结合部腺癌(GEJA)中国患者:DESTINY-Gastric06(DG-06)研究的最终分析
讲者:彭智 北京大学肿瘤医院
摘要号:132MO
英文标题:Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): updated results from a phase 1 study
中文标题:靶向claudin18.2(CLDN18.2)的抗体药物偶联物(ADC)IBI343用于晚期胰腺导管腺癌(PDAC)患者:Ⅰ期研究更新结果
讲者:虞先濬 复旦大学附属肿瘤医院
摘要号:74MO
英文标题:mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS CRC (BASKETⅡ): A Prospective, Single-Arm, Open-Label, Phase II Study
中文标题:mFOLFOX6联合贝伐珠单抗和PD-1单克隆抗体在局部晚期微卫星稳定型结直肠癌(MSS CRC)中的应用(BASKET II研究):一项前瞻性、单臂、开放标签、Ⅱ期研究。
讲者:黄俊 中山大学附属第六医院
泌尿生殖系统肿瘤
摘要号:268O
英文标题:Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
标题:肾细胞癌中新辅助免疫检查点抑制剂联合酪氨酸激酶抑制剂疗效的决定因素
讲者:顾良友(中国人民解放军总医院)
摘要号:272MO
英文标题:PUNCH01: Interim results from a phase II study of intra‑arterial chemotherapy(IAC)combined with Tislelizumab and Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)
标题:PUNCH01:动脉化疗(IAC)联合替雷利珠单抗和卡介苗(BCG)治疗高危非肌层浸润性膀胱癌(HR NMIBC)的II期临床试验中期结果
讲者:王宗任(中山大学附属第一医院)
摘要号:274MO
英文标题:Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial
标题:呋喹替尼联合斯鲁利单抗作为晚期非透明细胞肾细胞癌(nccRCC)一线治疗的疗效和安全性:一项单臂、多中心临床试验
讲者:黄吉炜(上海交通大学医学院附属仁济医院)
摘要号:276MO
英文标题:Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: a retrospective cohort study
标题:台湾局部晚期或转移性尿路上皮癌(la/mUC)患者(pts)的流行病学、治疗(tx)模式和临床结果:一项回顾性队列研究
讲者:Li-Nien Chien(中国台湾)
摘要号:336MO
英文标题:A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD): Interim Analysis of Efficacy
标题:帕米帕利治疗具有有害生殖细胞系或体细胞BRCA1/2变异或同源重组缺陷(HRD)的转移性去势抵抗性前列腺癌(mCRPC)患者的II期单臂开放标签试验:疗效中期分析
讲者:Diwei Zhao(中国广州)
摘要号:337MO
英文标题:Efficacy and safety of rezvilutamide (Rez) plus androgen-deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65–74, and ≥75 years: post-hoc analysis of randomized phase 3 CHART trial
标题:瑞维鲁胺(Rez)联合雄激素剥夺疗法(ADT)对年龄≤64岁、65–74岁和≥75岁高容量、转移性、激素敏感性前列腺癌(mHSPC)患者的疗效和安全性:随机化3期CHART 试验的事后分析
讲者:叶定伟(复旦大学附属肿瘤医院)
摘要号:338MO
英文标题:Efficacy and safety of Tislelizumab (T) combined with Gemcitabine and Cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical local surgery: a prospective, phase II study
标题:替雷利珠单抗(T)联合吉西他滨和顺铂(GC)治疗局部肌层浸润性膀胱癌(MIBC)患者根治性局部手术后的疗效和安全性:一项前瞻性II期研究
讲者:曹明(上海交通大学医学院附属仁济医院)
头颈肿瘤
摘要号:402O
英文标题:Preliminary Results of Phase II Study to Evaluate Safety and Efficacy of Combination Pucotenlimab with Epidermal Growth Factor Receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
中文标题:Pucotenlimab联合EGFR-ADC MRG003治疗复发或转移性鼻咽癌(R/M-NPC)的安全性和有效性:II期研究初步结果
讲者:徐瑞华 中山大学肿瘤防治中心
摘要号:403O
英文标题:Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
中文标题:替雷利珠单抗联合化疗对比安慰剂联合化疗用于复发或转移性鼻咽癌一线治疗:RATIONALE-309研究3年随访结果
讲者:方文峰 中山大学肿瘤防治中心
摘要号:407MO
英文标题:Capecitabine combined with PD-1 antibody as maintenance therapy after first-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study
中文标题:卡培他滨联合PD-1单抗用于复发或转移性鼻咽癌一线治疗后维持治疗:倾向评分匹配研究
讲者:Yifu Li (中国广州)
摘要号:LBA3
英文标题:First-line HLX07 vs. Placebo Combined with Serplulimab and Chemotherapy for Nasopharyngeal Cancer: a Randomised, Double-blind, Multicentre Phase 2 study
中文标题:HLX07对比安慰剂联合斯鲁利单抗和化疗一线治疗鼻咽癌:一项随机、双盲、多中心II期临床研究
讲者:张力 中山大学肿瘤防治中心
摘要号:408MO
英文标题:Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
中文标题:确定局部晚期鼻咽癌同步放化疗后辅助化疗的最佳时机
讲者:Hui Chen (中国广州)
摘要号:409MO
英文标题:Induction chemo-immunotherapy with camrelizumab plus modified TPF (nab-paclitaxel, cisplatin, and S1) in locally advanced nasopharyngeal carcinoma: A phase II, single-arm study
中文标题:卡瑞利珠单抗联合改良TPF(白蛋白结合型紫杉醇、顺铂和S1)用于局部晚期鼻咽癌诱导化学免疫治疗:一项II期单臂研究
讲者:吴三纲 厦门大学附属第一医院
摘要号:410MO
英文标题:Pattern and treatment outcomes of second primary cancer (SPC) of the upper aerodigestive tract (UADT) in head and neck squamous cell carcinoma (HNSCC) survivors: A multi-center retrospective cohort study with long-term follow-up
中文标题:头颈鳞癌(HNSCC)幸存者上呼吸消化道(UADT)第二原发癌(SPC)的模式和治疗结局:一项长期随访的多中心回顾性队列研究
讲者:Chak Ki J. Yung (中国香港)
发展和精准医学
摘要号:478O
英文标题:Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study
中文标题:口服PD-L1抑制剂ABSK043在晚期实体瘤患者中的1期研究的最新结果
讲者:虞永峰(上海市胸科医院)
摘要号:57O
英文标题:A phase 1/2 multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors
中文标题:DB-1311/BNT324(一种新型B7H3 ADC)在晚期实体瘤患者中的多中心、首次人体1/2期研究
讲者:程颖(吉林省肿瘤医院)
摘要号:58O
英文标题:Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8 agonist
中文标题:BM201(一种TLR7/8激动剂)首次人体研究的临床疗效、安全性和PK/PD结果
讲者:李茹恬(南京鼓楼医院)
摘要号:59O
英文标题:A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
中文标题:BPI-371153(一种新型小分子PD-L1抑制剂)在晚期实体瘤或复发/难治性(r/r)淋巴瘤中的首次人体、I期研究
讲者:杨建良(中国医学科学院肿瘤医院)
摘要号:61O
英文标题:Updated results of a phase II trial evaluating an Anti-EpCAM x Anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites
中文标题:II期试验最新结果:评估抗EpCAM x 抗CD3双特异性抗体M701治疗恶性腹水的效果
讲者:刘容锐(中国人民解放军总医院)
支持和姑息治疗
摘要号:528MO
英文标题:Cognitive Phenotypes and its Association with Role Functioning Outcomes in Adolescents and Young Adults (AYAs) with Cancer
中文标题:认知表型及其与青少年和年轻成年(AYAs)癌症患者角色功能结果的关联
讲者:Panpan Xiao(中国香港)
如有遗漏或错误,欢迎广大读者提醒及指正。
点击以下图片,获取更多ESMO Asia 2024专栏资讯!
排版编辑:TY